Mölnlycke latest news
Read news and updates about our company.
March 17, 2020
How we handle the Covid-19 situation
Being a provider of medical devices for health care professionals – many of which are critically needed to combat the evolving COVID-19 situation –...
May 29, 2020
Zlatko Rihter appointed new CEO of Mölnlycke
Zlatko Rihter has been appointed President and CEO of the medical solutions company, Mölnlycke Health Care AB.
One third of surgeons and nurses experience harmful allergic reactions in the operating theatre
24 September 2020: With surgeons and nurses working to clear the elective backlog from coronavirus, a new global survey has revealed they are suffering...
Barry McBride to take on the position as interim CEO
Gothenburg – 24 July 2020 Barry McBride, EVP Gloves, Antiseptics and Global R&D, will take on the role as interim CEO as of 1 August and until the new...
AstraZeneca’s BioVentureHub and Mölnlycke collaborate to support knowledge exchange across the Swedish life science industry
AstraZeneca’s BioVentureHub announced today that it has established a new collaboration with Mölnlycke, a global medtech company headquartered in...
Medical Device Regulation (MDR) to be postponed
The Medical Device Regulation (MDR) – which was due to enter into force in May this year –will replace the Medical Device Directive in Europe and is muc...
Mölnlycke employees volunteering at the front line
Mölnlycke takes pride in having a highly trained workforce as many of our employees have a clinical background.
Mölnlycke supplies Swedish National Board of Health and Welfare with additional 12 million face masks
By utilising its extensive global supplier network, the world-leading medical solutions company, Mölnlycke has managed to contract suppliers for...
French export ban for face masks lifted
Thanks to crucial efforts by the Swedish Prime Minister Stefan Löfven and several other parties, the French government has today decided to lift the...
CEO Richard Twomey leaves Mölnlycke
Richard Twomey, President and CEO of Mölnlycke, will after six years leave the organisation.
New cost benefit analysis reports NHS chronic wound care costs can be reduced by use of haemoglobin spray
New report shows Granulox ® (Mölnlycke), an innovative topical haemoglobin spray, is a cost-effective therapy in chronic wound care management as adjunc...
Mölnlycke acquires German wound care company SastoMed GmbH
The world-leading medical solutions company, Mölnlycke, has acquired German wound care products company, SastoMed GmbH. The deal adds new, award-winning...
Creating opportunities at AZ BioVenture Hub
Just a few months since Mölnlycke signed a partnership with AstraZeneca BioVenture Hub, and it has already resulted in collaboration and building...